Principal Clinical Data Scientist
Boehringer Ingelheim Pharmaceuticals Inc
Victoria Chen is a Prinicpal Clinical Data Scientist at Boehringer Ingelheim. Victoria is currently the trial statistician of the BI Brightline-1 trial: A Phase II/III, randomized, open-label, multicenter study of the MDM2–p53 antagonist BI 907828 vs doxorubicin in the first-line treatment of patients with dedifferentiated liposarcoma. Enrollment for the trial is currently ongoing.